User profiles for Matthieu Groh
 | Matthieu GrohDepartment of Internal Medicine, National Reference Center for Hypereosinophilic … Verified email at hopital-foch.com Cited by 3799 |
[HTML][HTML] Eosinophilic granulomatosis with polyangiitis (Churg–Strauss)(EGPA) Consensus Task Force recommendations for evaluation and management
M Groh, C Pagnoux, C Baldini, E Bel, P Bottero… - European journal of …, 2015 - Elsevier
Objective To develop disease-specific recommendations for the diagnosis and management
of eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) (EGPA). …
of eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) (EGPA). …
[HTML][HTML] Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
…, F Schneider, MC Taquet, M Groh… - The Lancet …, 2021 - thelancet.com
Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity.
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …
[HTML][HTML] Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients
Objectives To assess efficacy and safety of rituximab (RTX) as induction therapy,
maintenance of remission and treatment of relapses in a cohort of IgG4-related disease (IgG4-RD) …
maintenance of remission and treatment of relapses in a cohort of IgG4-related disease (IgG4-RD) …
Adding azathioprine to remission‐induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg‐Strauss), microscopic polyangiitis, or polyarteritis …
Objective In most patients with nonsevere systemic necrotizing vasculitides ( SNV s), remission
is achieved with glucocorticoids alone, but one‐third experience a relapse within 2 years. …
is achieved with glucocorticoids alone, but one‐third experience a relapse within 2 years. …
Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)
…, P Sivasothy, ME Wechsler, M Groh… - European …, 2016 - Eur Respiratory Soc
The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have
not been studied in detail. In this retrospective multicentre study, EGPA was defined by …
not been studied in detail. In this retrospective multicentre study, EGPA was defined by …
Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency
Background Immunocompromised patients are at increased risk for severe influenza and
invasive pneumococcal diseases. Population-specific vaccine recommendations are thus …
invasive pneumococcal diseases. Population-specific vaccine recommendations are thus …
Interleukin-6 blockade for severe COVID-19
M Roumier, R Paule, M Groh, A Vallée, F Ackermann… - medrxiv, 2020 - medrxiv.org
In the context of COVID-19 pandemic and growing tensions worldwide regarding healthcare
facilities, there is an urgent need for effective treatments likely to reduce the crunch of ICU …
facilities, there is an urgent need for effective treatments likely to reduce the crunch of ICU …
Anti‐IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): data on seventeen patients
…, H Gil, B Bienvenu, A Coste, M Groh… - Arthritis & …, 2016 - Wiley Online Library
Objective To describe the efficacy and safety of omalizumab, an anti‐IgE monoclonal antibody,
in patients with refractory and/or relapsing eosinophilic granulomatosis with polyangiitis (…
in patients with refractory and/or relapsing eosinophilic granulomatosis with polyangiitis (…
Use of biologics to treat relapsing and/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study
…, S Sartorelli, AM Ruppert, M Groh… - Arthritis & …, 2021 - Wiley Online Library
Objective To describe the efficacy and safety of biologics for the treatment of eosinophilic
granulomatosis with polyangiitis (EGPA). Methods A retrospective European collaborative …
granulomatosis with polyangiitis (EGPA). Methods A retrospective European collaborative …
[HTML][HTML] Ophthalmic manifestations in IgG4-related disease: clinical presentation and response to treatment in a French case-series
M Ebbo, M Patient, A Grados, M Groh, J Desblaches… - Medicine, 2017 - journals.lww.com
IgG4-related disease (IgG4-RD) is characterized by variable tissue or organ involvements
sharing common pathological findings. Orbital or orbital adnexa involvement of the disease …
sharing common pathological findings. Orbital or orbital adnexa involvement of the disease …